Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

NCT03620643 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT03620643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03620643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 2
Overall status
Completed
Start date
May 9, 2019
Completion date
August 30, 2024
Enrollment
33 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cdh1 gene mutation, gastric cancer, lobular breast carcinoma, triple negative breast cancer